Non-segmental Vitiligo
Conditions
Brief summary
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
Interventions
oral administration
oral administration
Sponsors
Study design
Eligibility
Inclusion criteria
1. Provide written informed consent. 2. Male or female ≥ 18 years of age at time of screening 3. Stable (without new patches ≥ 1 year) or unstable (with new patches for the last 1 year) vitiligo 4. VASI of ≥ 4 at screening and baseline
Exclusion criteria
1. Segmental vitiligo, focal, or mixed Vitiligo 2. Subjects who have high risk of suicidality at the Screening assessment based on Investigator's judgment 3. History of alcohol or drug abuse in the previous 2 years 4. Subjects who were submitted to melanocyte transfer \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in Vitiligo Area Scoring Index Score | Week 24 | Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures | Week 24 | The Vitiligo Extent Score (VES) measures the overall vitiligo involvement in the body based on clinical pictures reflecting the natural distribution of the disease across 19 body areas (e.g., face, trunk, arms, legs, hands, axillae, back, gluteal). For each area, one representative image is selected, assigning one of six degrees of involvement (1%, 5%, 10%, 25%, 50%, 75%). The total and final score is the sum of the measurements from all areas, calculated using a conversion table available in the online calculator (www.vitiligo-calculator.com), and expressed as the extension of body surface area affected (0-100). Higher scores indicate worse clinical involvement. The VES change from baseline to Week 24 was assessed for the ITT population. |
| Mean Change in Vitiligo Impact Patient Scale | Week 24 | Subjects will be asked to complete a questionnaire to assess the burden experienced by individuals affected. For each of the statements in the Vitiligo Impact Patient Scale, 7 responses are suggested: always, very often, often, sometimes, rarely, never and not applicable. The individual answered as spontaneously as possible while thinking about their situation over the last 7 days. Summary scores range from 0 to 100. Higher values indicate a worse clinical condition. |
| Physician's Global Assessment Scores | Week 52 | Description: The investigator will perform an average assessment of all vitiligo lesions. The following scale will be used for the PGA: Score 0= No involvement, Score 1= Limited, Score 2= moderate, Score 3= Extensive or Score 4= Very extensive. Higher values indicate a worse clinical condition. The static Physician's Global Assessment determines vitiligo extend at a single point in time, without taking the baseline disease condition into consideration, in other words, represents the Proportion of subjects achieving a PGA score of no involvement (score 0) or limited extent (score 1) with at least 2-point reduction from Baseline Week 52. |
| Mean Change From Baseline in Dermatology Life Quality Index | Week 52 | The DLQI scores are based on the response from the patient. Each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired OR lower scores indicate better quality of life. |
Countries
India, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Placebo | 59 |
| Placebo to AS012 Dose Regimen II at Week 24 Placebo to AS012 dose 2x at Week 24 | 20 |
| Placebo to AS012 Dose Regimen IV at Week 24 Placebo to AS012 dose 6x at Week 24 | 20 |
| AS012 Dose Regimen I AS012 dose x | 62 |
| AS012 Dose Regimen II AS012 dose 2x | 71 |
| AS012 Dose Regimen III AS012 dose 4x | 63 |
| AS012 Dose Regimen IV AS012 dose 6x | 72 |
| Total | 367 |
Baseline characteristics
| Characteristic | Placebo | AS012 Dose Regimen I | AS012 Dose Regimen II | AS012 Dose Regimen III | AS012 Dose Regimen IV | Total | Placebo to AS012 Dose Regimen II at Week 24 | Placebo to AS012 Dose Regimen IV at Week 24 |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous Placebo and AS012 Regimens | 44.2 years STANDARD_DEVIATION 14.65 | 48.1 years STANDARD_DEVIATION 14.85 | 45.2 years STANDARD_DEVIATION 12.87 | 46.8 years STANDARD_DEVIATION 14.52 | 41.8 years STANDARD_DEVIATION 15.18 | 45.1 years STANDARD_DEVIATION 14.49 | — | — |
| Age, Continuous Placebo to AS012 Regimens | — | — | — | — | — | 44.5 years STANDARD_DEVIATION 15.66 | 45.6 years STANDARD_DEVIATION 14.81 | 43.3 years STANDARD_DEVIATION 16.76 |
| Ethnicity (NIH/OMB) Placebo and AS012 Regimens Hispanic or Latino | 19 Participants | 18 Participants | 17 Participants | 15 Participants | 16 Participants | 85 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Placebo and AS012 Regimens Not Hispanic or Latino | 40 Participants | 44 Participants | 54 Participants | 48 Participants | 56 Participants | 242 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Placebo and AS012 Regimens Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Placebo to AS012 Regimens Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 14 Participants | 8 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Placebo to AS012 Regimens Not Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 26 Participants | 12 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Placebo to AS012 Regimens Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Placebo and AS012 Regimens Female | 31 Participants | 32 Participants | 38 Participants | 36 Participants | 34 Participants | 171 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Placebo and AS012 Regimens Male | 28 Participants | 30 Participants | 33 Participants | 27 Participants | 38 Participants | 156 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Placebo to AS012 Regimens Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 19 Participants | 11 Participants | 8 Participants |
| Sex: Female, Male Placebo to AS012 Regimens Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 21 Participants | 9 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 59 | 0 / 62 | 0 / 70 | 0 / 63 | 0 / 72 | 0 / 20 | 0 / 20 | 0 / 44 | 0 / 59 | 0 / 46 | 0 / 54 | 0 / 162 |
| other Total, other adverse events | 0 / 59 | 0 / 62 | 0 / 70 | 0 / 63 | 0 / 72 | 1 / 20 | 0 / 20 | 0 / 44 | 0 / 59 | 0 / 46 | 0 / 54 | 0 / 162 |
| serious Total, serious adverse events | 0 / 59 | 0 / 62 | 0 / 70 | 0 / 63 | 0 / 72 | 0 / 20 | 0 / 20 | 0 / 44 | 0 / 59 | 0 / 46 | 0 / 54 | 0 / 162 |
Outcome results
Mean Change From Baseline in Vitiligo Area Scoring Index Score
Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state
Time frame: Week 24
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Change From Baseline in Vitiligo Area Scoring Index Score | -0.472 score on a scale | Standard Deviation 1.0422 |
| AS012 Dose Regimen I | Mean Change From Baseline in Vitiligo Area Scoring Index Score | -0.271 score on a scale | Standard Deviation 2.5139 |
| AS012 Dose Regimen II | Mean Change From Baseline in Vitiligo Area Scoring Index Score | -0.706 score on a scale | Standard Deviation 1.7301 |
| AS012 Dose Regimen III | Mean Change From Baseline in Vitiligo Area Scoring Index Score | -1.145 score on a scale | Standard Deviation 2.7721 |
| AS012 Dose Regimen IV | Mean Change From Baseline in Vitiligo Area Scoring Index Score | -0.110 score on a scale | Standard Deviation 2.6168 |
Mean Change From Baseline in Dermatology Life Quality Index
The DLQI scores are based on the response from the patient. Each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired OR lower scores indicate better quality of life.
Time frame: Week 52
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Change From Baseline in Dermatology Life Quality Index | 0.2 score on a scale | Standard Deviation 2.12 |
| AS012 Dose Regimen I | Mean Change From Baseline in Dermatology Life Quality Index | 0.0 score on a scale | Standard Deviation 3.33 |
| AS012 Dose Regimen II | Mean Change From Baseline in Dermatology Life Quality Index | -0.8 score on a scale | Standard Deviation 3.08 |
| AS012 Dose Regimen III | Mean Change From Baseline in Dermatology Life Quality Index | -0.6 score on a scale | Standard Deviation 4.76 |
| AS012 Dose Regimen IV | Mean Change From Baseline in Dermatology Life Quality Index | -2.0 score on a scale | Standard Deviation 3.49 |
| AS012 Dose Regimen IV | Mean Change From Baseline in Dermatology Life Quality Index | -0.2 score on a scale | Standard Deviation 2.51 |
Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures
The Vitiligo Extent Score (VES) measures the overall vitiligo involvement in the body based on clinical pictures reflecting the natural distribution of the disease across 19 body areas (e.g., face, trunk, arms, legs, hands, axillae, back, gluteal). For each area, one representative image is selected, assigning one of six degrees of involvement (1%, 5%, 10%, 25%, 50%, 75%). The total and final score is the sum of the measurements from all areas, calculated using a conversion table available in the online calculator (www.vitiligo-calculator.com), and expressed as the extension of body surface area affected (0-100). Higher scores indicate worse clinical involvement. The VES change from baseline to Week 24 was assessed for the ITT population.
Time frame: Week 24
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures | -0.507 score on a scale | Standard Deviation 1.7427 |
| AS012 Dose Regimen I | Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures | -0.671 score on a scale | Standard Deviation 2.2065 |
| AS012 Dose Regimen II | Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures | -0.284 score on a scale | Standard Deviation 2.4793 |
| AS012 Dose Regimen III | Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures | -0.454 score on a scale | Standard Deviation 2.1214 |
| AS012 Dose Regimen IV | Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures | -1.218 score on a scale | Standard Deviation 3.3963 |
Mean Change in Vitiligo Impact Patient Scale
Subjects will be asked to complete a questionnaire to assess the burden experienced by individuals affected. For each of the statements in the Vitiligo Impact Patient Scale, 7 responses are suggested: always, very often, often, sometimes, rarely, never and not applicable. The individual answered as spontaneously as possible while thinking about their situation over the last 7 days. Summary scores range from 0 to 100. Higher values indicate a worse clinical condition.
Time frame: Week 24
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Change in Vitiligo Impact Patient Scale | -2.72 score on a scale | Standard Deviation 12.575 |
| AS012 Dose Regimen I | Mean Change in Vitiligo Impact Patient Scale | -3.48 score on a scale | Standard Deviation 13.603 |
| AS012 Dose Regimen II | Mean Change in Vitiligo Impact Patient Scale | -4.24 score on a scale | Standard Deviation 18.984 |
| AS012 Dose Regimen III | Mean Change in Vitiligo Impact Patient Scale | -2.50 score on a scale | Standard Deviation 11.506 |
| AS012 Dose Regimen IV | Mean Change in Vitiligo Impact Patient Scale | -2.06 score on a scale | Standard Deviation 15.082 |
Physician's Global Assessment Scores
Description: The investigator will perform an average assessment of all vitiligo lesions. The following scale will be used for the PGA: Score 0= No involvement, Score 1= Limited, Score 2= moderate, Score 3= Extensive or Score 4= Very extensive. Higher values indicate a worse clinical condition. The static Physician's Global Assessment determines vitiligo extend at a single point in time, without taking the baseline disease condition into consideration, in other words, represents the Proportion of subjects achieving a PGA score of no involvement (score 0) or limited extent (score 1) with at least 2-point reduction from Baseline Week 52.
Time frame: Week 52
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Physician's Global Assessment Scores | 0 Participants |
| AS012 Dose Regimen I | Physician's Global Assessment Scores | 0 Participants |
| AS012 Dose Regimen II | Physician's Global Assessment Scores | 0 Participants |
| AS012 Dose Regimen III | Physician's Global Assessment Scores | 0 Participants |
| AS012 Dose Regimen IV | Physician's Global Assessment Scores | 1 Participants |
| AS012 Dose Regimen IV | Physician's Global Assessment Scores | 0 Participants |